Unanswered questions following reports of secondary malignancies after CAR-T cell therapy Editorial

  

Authors:	Levine, B. L.; Pasquini, M. C.; Connolly, J. E.; Porter, D. L.; Gustafson, M. P.; Boelens, J. J.; Horwitz, E. M.; Grupp, S. A.; Maus, M. V.; Locke, F. L.; Ciceri, F.; Ruggeri, A.; Snowden, J.; Heslop, H. E.; Mackall, C. L.; June, C. H.; Sureda, A. M.; Perales, M. A.
Title:	Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Abstract:	Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments. © Springer Nature America, Inc. 2024.
Keywords:	note; metastasis; pathology; b cell lymphoma; lymphoma, b-cell; hematologic neoplasms; chimeric antigen receptor; biological therapy; adoptive immunotherapy; immunotherapy, adoptive; hematologic disease; humans; human; cell- and tissue-based therapy; chimeric antigen receptor t-cell immunotherapy; receptors, chimeric antigen
Journal Title:	Nature Medicine
Volume:	30
Issue:	2
ISSN:	1078-8956
Publisher:	Nature Publishing Group
Date Published:	2024-02-01
Start Page:	338
End Page:	341
Language:	English
DOI:	10.1038/s41591-023-02767-w
PUBMED:	38195751
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181956361&doi=10.1038%2fs41591-023-02767-w&partnerID=40&md5=0073b8d437111b7214c701de98d30012
Notes:	Note -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/214057